- Home
- REGN vs CRWD Comparison
REGN vs CRWD Comparison
Compare REGN & CRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- CRWD
- Stock Information
- Founded
- REGN 1988
- CRWD 2011
- Country
- REGN United States
- CRWD United States
- Employees
- REGN N/A
- CRWD N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- CRWD EDP Services
- Sector
- REGN Health Care
- CRWD Technology
- Exchange
- REGN Nasdaq
- CRWD Nasdaq
- Market Cap
- REGN 63.4B
- CRWD N/A
- IPO Year
- REGN 1991
- CRWD 2019
- Fundamental
- Price
- REGN $547.67
- CRWD $428.63
- Analyst Decision
- REGN Buy
- CRWD Buy
- Analyst Count
- REGN 23
- CRWD 47
- Target Price
- REGN $907.39
- CRWD $404.89
- AVG Volume (30 Days)
- REGN 1.2M
- CRWD 3.5M
- Earning Date
- REGN 04-29-2025
- CRWD 06-03-2025
- Dividend Yield
- REGN 0.32%
- CRWD N/A
- EPS Growth
- REGN 16.49
- CRWD N/A
- EPS
- REGN 39.43
- CRWD N/A
- Revenue
- REGN $14,085,700,000.00
- CRWD $3,953,624,000.00
- Revenue This Year
- REGN $2.38
- CRWD $23.15
- Revenue Next Year
- REGN $7.65
- CRWD $21.46
- P/E Ratio
- REGN $14.23
- CRWD N/A
- Revenue Growth
- REGN 7.52
- CRWD 29.39
- 52 Week Low
- REGN $520.50
- CRWD $200.81
- 52 Week High
- REGN $1,211.20
- CRWD $455.59
- Technical
- Relative Strength Index (RSI)
- REGN 38.69
- CRWD 59.94
- Support Level
- REGN $542.44
- CRWD $417.06
- Resistance Level
- REGN $615.61
- CRWD $451.15
- Average True Range (ATR)
- REGN 22.06
- CRWD 14.00
- MACD
- REGN -0.13
- CRWD 2.06
- Stochastic Oscillator
- REGN 28.57
- CRWD 76.42
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).